

CITATION REPORT

List of articles citing

The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom

DOI: [10.3390/vaccines9060598](https://doi.org/10.3390/vaccines9060598)

Vaccines, 2021, 9, .

Source: <https://exaly.com/paper-pdf/81075787/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
6	The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom. <i>Human Vaccines and Immunotherapeutics</i> , 2021 , 1-8	4.4	1
5	An Economic Comparison of Influenza Vaccines Recommended for Use in Eligible Adults under 65 Years in the United Kingdom.. <i>Vaccines</i> , 2022 , 10,	5.3	0
4	A Profile of Influenza Vaccine Coverage for 2019-2020: a Database Study of the English Primary Care Sentinel Cohort (Preprint).		
3	Review of Analyses Estimating Relative Vaccine Effectiveness of Cell-Based Quadrivalent Influenza Vaccine in Three Consecutive US Influenza Seasons. <i>Vaccines</i> , 2022 , 10, 896	5.3	0
2	Incorporating productivity loss in health economic evaluations: a review of guidelines and practices worldwide for research agenda in China. 2022 , 7, e009777		0
1	Estimating the impact of influenza vaccination of low-risk 50-64-year-olds on acute and ICU hospital bed usage in an influenza season under endemic COVID-19 in the UK. 2023 , 19,		0